Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more
Living Cell Technologies Limited (LVCLF) - Net Assets
Latest net assets as of June 2025: $2.23 Million USD
Based on the latest financial reports, Living Cell Technologies Limited (LVCLF) has net assets worth $2.23 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.40 Million) and total liabilities ($169.76K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.23 Million |
| % of Total Assets | 92.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | 61.85% |
| 10-Year Change | -60.74% |
| Growth Volatility | 167.73 |
Living Cell Technologies Limited - Net Assets Trend (2004–2025)
This chart illustrates how Living Cell Technologies Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Living Cell Technologies Limited (2004–2025)
The table below shows the annual net assets of Living Cell Technologies Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $2.23 Million | -26.06% |
| 2024-06-30 | $3.01 Million | -19.88% |
| 2023-06-30 | $3.76 Million | -6.76% |
| 2022-06-30 | $4.03 Million | +192.99% |
| 2021-06-30 | $1.38 Million | -52.16% |
| 2020-06-30 | $2.88 Million | -30.45% |
| 2019-06-30 | $4.14 Million | -42.00% |
| 2018-06-30 | $7.14 Million | -5.09% |
| 2017-06-30 | $7.52 Million | +32.44% |
| 2016-06-30 | $5.68 Million | +10.72% |
| 2015-06-30 | $5.13 Million | -39.19% |
| 2014-06-30 | $8.43 Million | -36.38% |
| 2013-06-30 | $13.25 Million | -7.67% |
| 2012-06-30 | $14.35 Million | +112.32% |
| 2011-06-30 | $6.76 Million | +8.34% |
| 2010-06-30 | $6.24 Million | +12.89% |
| 2009-06-30 | $5.53 Million | -52.05% |
| 2008-06-30 | $11.53 Million | +722.59% |
| 2007-06-30 | $1.40 Million | -19.63% |
| 2006-06-30 | $1.74 Million | -44.39% |
| 2005-06-30 | $3.14 Million | +336.57% |
| 2004-06-30 | $-1.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Living Cell Technologies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6957756400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $81.54 Million | 3658.51% |
| Other Comprehensive Income | $573.33K | 25.72% |
| Total Equity | $2.23 Million | 100.00% |
Living Cell Technologies Limited Competitors by Market Cap
The table below lists competitors of Living Cell Technologies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EPS Bio Technology Corp.
TWO:4183
|
$4.27 Million |
|
Carolina Rush Corporation
V:RUSH
|
$4.27 Million |
|
MainStreetChamber Holdings Inc.
PINK:MSCH
|
$4.27 Million |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
$4.27 Million |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
$4.27 Million |
|
AB Panevezio Statybos Trestas
STU:YK3
|
$4.27 Million |
|
Forza Land Indonesia Tbk PT
JK:FORZ
|
$4.26 Million |
|
PP PRIME Public Company Limited
BK:PPPM
|
$4.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Living Cell Technologies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,014,250 to 2,228,796, a change of -785,454 (-26.1%).
- Net loss of 802,958 reduced equity.
- Other comprehensive income increased equity by 16,254.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-802.96K | -36.03% |
| Other Comprehensive Income | $16.25K | +0.73% |
| Other Changes | $1.25K | +0.06% |
| Total Change | $- | -26.06% |
Book Value vs Market Value Analysis
This analysis compares Living Cell Technologies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | $-0.06 | $0.00 | x |
| 2005-06-30 | $0.04 | $0.00 | x |
| 2006-06-30 | $0.02 | $0.00 | x |
| 2007-06-30 | $0.01 | $0.00 | x |
| 2008-06-30 | $0.06 | $0.00 | x |
| 2009-06-30 | $0.02 | $0.00 | x |
| 2010-06-30 | $0.02 | $0.00 | x |
| 2011-06-30 | $0.02 | $0.00 | x |
| 2012-06-30 | $0.04 | $0.00 | x |
| 2013-06-30 | $0.04 | $0.00 | x |
| 2014-06-30 | $0.02 | $0.00 | x |
| 2015-06-30 | $0.01 | $0.00 | x |
| 2016-06-30 | $0.01 | $0.00 | x |
| 2017-06-30 | $0.01 | $0.00 | x |
| 2018-06-30 | $0.01 | $0.00 | x |
| 2019-06-30 | $0.01 | $0.00 | x |
| 2020-06-30 | $0.00 | $0.00 | x |
| 2021-06-30 | $0.00 | $0.00 | x |
| 2022-06-30 | $0.00 | $0.00 | x |
| 2023-06-30 | $0.00 | $0.00 | x |
| 2024-06-30 | $0.00 | $0.00 | x |
| 2025-06-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Living Cell Technologies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-36.03%) is above the historical average (-96.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -14175.77% | 0.06x | 0.00x | $-10.18 Million |
| 2005 | -194.46% | -9321.39% | 0.02x | 1.26x | $-6.41 Million |
| 2006 | -391.12% | -521775.90% | 0.00x | 2.44x | $-6.99 Million |
| 2007 | -427.26% | -32731.92% | 0.00x | 2.72x | $-6.13 Million |
| 2008 | -58.94% | -13079.04% | 0.00x | 1.06x | $-7.95 Million |
| 2009 | -110.79% | -3284.06% | 0.03x | 1.18x | $-6.68 Million |
| 2010 | -90.94% | -1097.31% | 0.07x | 1.11x | $-6.30 Million |
| 2011 | -100.52% | -3849.43% | 0.02x | 1.11x | $-7.47 Million |
| 2012 | 39.55% | 153.07% | 0.24x | 1.08x | $4.24 Million |
| 2013 | -22.48% | -39.30% | 0.53x | 1.07x | $-4.30 Million |
| 2014 | -80.40% | -91.68% | 0.77x | 1.15x | $-7.62 Million |
| 2015 | -137.38% | -1150.97% | 0.11x | 1.07x | $-7.56 Million |
| 2016 | -54.49% | -2575.68% | 0.02x | 1.11x | $-3.66 Million |
| 2017 | -54.40% | -3548.14% | 0.01x | 1.16x | $-4.84 Million |
| 2018 | -5.25% | -308.47% | 0.02x | 1.07x | $-1.09 Million |
| 2019 | -76.87% | -32565.90% | 0.00x | 1.39x | $-3.60 Million |
| 2020 | -33.65% | -30570.36% | 0.00x | 1.18x | $-1.26 Million |
| 2021 | -106.06% | -544.62% | 0.16x | 1.19x | $-1.60 Million |
| 2022 | -48.51% | -57483.11% | 0.00x | 1.06x | $-2.36 Million |
| 2023 | -56.02% | -5016.32% | 0.01x | 1.12x | $-2.48 Million |
| 2024 | -69.52% | -1673.77% | 0.04x | 1.06x | $-2.40 Million |
| 2025 | -36.03% | 0.00% | 0.00x | 1.08x | $-1.03 Million |
Industry Comparison
This section compares Living Cell Technologies Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Living Cell Technologies Limited (LVCLF) | $2.23 Million | 0.00% | 0.08x | $4.27 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |